Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.38 |
| ▸ | RXRA | P19793 | 10/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896662 | 0.81 | TAAR1 (0.41) | NR1H2NR1H3RXRANR1I2EPAS1 | |
| SCHEMBL16904921 | 0.81 | PTGS2 (0.37) | NR1H2NR1H3RXRANR1I2EPAS1 | |
| SCHEMBL20690108 | 0.78 | NR1H2 (0.38) | NR1H2NR1H3RXRANR1I2EPAS1 | |
| SCHEMBL18589754 | 0.77 | ADRB2 (0.43) | NR1H2NR1H3RXRANR1I2EPAS1 | |
| SCHEMBL378361 | 0.77 | TAAR1 (0.34) | — | |
| SCHEMBL20661619 | 0.74 | KMT2A (0.42) | — | |
| SCHEMBL16896840 | 0.73 | GPR119 (0.38) | NR1H2NR1H3RXRAEPAS1 | |
| SCHEMBL14485312 | 0.73 | ACVRL1 (0.33) | — | |
| SCHEMBL17419026 | 0.72 | HTR1D (0.35) | — | |
| SCHEMBL29546230 | 0.72 | HTR1D (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020148325-A1 | NEUTRAL LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-07-23 | — | — | WO | disclosed |
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| CN-102648184-A | LXR modulators | EXELIXIS PATENT CO LLC | 2012-08-22 | — | — | CN | disclosed |
| EP-2435410-A2 | LXR MODULATORS | Exelixis Patent Company LLC (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163081-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885RXRA 10/4885 |
| US-10669296-B2 | LXR agonists and uses thereof | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885RXRA 13/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885RXRA 10/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 26/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 26/4885 |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.